Literature DB >> 27220777

Hsa-miR-495 acts as a tumor suppressor gene in glioma via the negative regulation of MYB.

Benping Zhang1, Fei Yuan2, Jie Liu2, Yang Li2, Fucheng Zhou2, Xuanxi Liu2, Zhen Hao2, Qingsong Li2, Yongri Zheng2, Weizhi Wang1.   

Abstract

MicroRNAs (miRNAs) are small non-coding RNA molecules that regulate gene expression at the post-transcriptional level. Previous studies have reported that there are causative links between the abnormal regulation of miRNAs and cancer development. Hsa‑miR‑495 has previously been demonstrated to be downregulated, and to function as a tumor suppressor, in numerous types of human cancer. However, the function and molecular mechanism of hsa‑miR‑495 in glioma remains unclear. In the current study, the expression and effects of hsa‑miR‑495 on glioma were evaluated. It was identified that the expression levels of hsa-miR-495 were downregulated in glioma tissues and cell lines. Furthermore, restoration of hsa-miR-495 inhibited glioma cell proliferation and invasion in vitro. Notably, a luciferase reporter assay revealed that hsa‑miR‑495 was able to directly target v‑myb avian myeloblastosis viral oncogene homolog (MYB) in glioma cells. In addition, an RNA interference assay indicated that MYB knockdown inhibited glioma cell proliferation and invasion in vitro. In conclusion, the results of the present study suggested that hsa‑miR‑495 may act as a tumor suppressor gene in glioma by directly inhibiting MYB expression, which may provide a novel therapeutic strategy for the treatment of glioma.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27220777     DOI: 10.3892/mmr.2016.5327

Source DB:  PubMed          Journal:  Mol Med Rep        ISSN: 1791-2997            Impact factor:   2.952


  8 in total

1.  MicroRNA-495 suppresses cell proliferation and invasion of hepatocellular carcinoma by directly targeting insulin-like growth factor receptor-1.

Authors:  Ying Ye; Juhua Zhuang; Guangdong Wang; Saifei He; Suiliang Zhang; Guoyu Wang; Jing Ni; Jiening Wang; Wei Xia
Journal:  Exp Ther Med       Date:  2017-11-08       Impact factor: 2.751

Review 2.  Targeting MicroRNAs in Cancer Gene Therapy.

Authors:  Weidan Ji; Bin Sun; Changqing Su
Journal:  Genes (Basel)       Date:  2017-01-09       Impact factor: 4.096

3.  miR-495 inhibits proliferation, migration, and invasion and induces apoptosis via inhibiting PBX3 in melanoma cells.

Authors:  Guangxiong Chen; Yijie Xie
Journal:  Onco Targets Ther       Date:  2018-04-05       Impact factor: 4.147

4.  miR-495 inhibits the growth of fibroblasts in hypertrophic scars.

Authors:  Bingyu Guo; Qiang Hui; Zhishan Xu; Peng Chang; Kai Tao
Journal:  Aging (Albany NY)       Date:  2019-05-14       Impact factor: 5.682

Review 5.  Intricate crosstalk between MYB and noncoding RNAs in cancer.

Authors:  Dingyu Hu; Wenjun Shao; Li Liu; Yanyan Wang; Shunling Yuan; Zhaoping Liu; Jing Liu; Ji Zhang
Journal:  Cancer Cell Int       Date:  2021-12-07       Impact factor: 5.722

6.  Evaluation of the Synergistic Potential of Simultaneous Pan- or Isoform-Specific BET and SYK Inhibition in B-Cell Lymphoma: An In Vitro Approach.

Authors:  Sina Sender; Ahmad Wael Sultan; Daniel Palmer; Dirk Koczan; Anett Sekora; Julia Beck; Ekkehard Schuetz; Leila Taher; Bertram Brenig; Georg Fuellen; Christian Junghanss; Hugo Murua Escobar
Journal:  Cancers (Basel)       Date:  2022-09-27       Impact factor: 6.575

7.  Downregulation of MicroRNA-495 Alleviates IL-1β Responses among Chondrocytes by Preventing SOX9 Reduction.

Authors:  Soyeong Joung; Dong Suk Yoon; Sehee Cho; Eun Ae Ko; Kyoung Mi Lee; Kwang Hwan Park; Jin Woo Lee; Sung Hwan Kim
Journal:  Yonsei Med J       Date:  2021-07       Impact factor: 2.759

8.  miR-150 Suppresses Tumor Growth in Melanoma Through Downregulation of MYB.

Authors:  Xiyan Sun; Chao Zhang; Yang Cao; Erbiao Liu
Journal:  Oncol Res       Date:  2018-04-24       Impact factor: 5.574

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.